Boya Bio-Pharmaceutical shareholders approve independent director appointments, subsidies

Boya Bio-Pharmaceutical Group held its third extraordinary general meeting of shareholders in 2025 on December 12, 2025. The meeting, convened by the board and chaired by Qiu Kai, addressed two key proposals.

The first resolution, "Proposal on the Appointment of an Independent Director for the Eighth Board of Directors," was approved with 98.8688% of shares voting in favor. This confirms the appointment of Li Changqing as an independent director. The second resolution, "Proposal on the Subsidies for Independent Directors of the Company's Eighth Board of Directors," also passed with 98.6469% of votes in favor, allocating subsidies to the newly appointed independent directors.

A total of 285 shareholders, representing 44.3466% of the company's voting shares (223,617,060 shares), participated in the meeting, either in person or through online voting. Beijing Dacheng Law Offices confirmed the legality and validity of the meeting's procedures, attendee qualifications, and resolution outcomes.